A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

Registration Number
NCT06719011
Lead Sponsor
Novo Nordisk A/S
Brief Summary

This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants will either get the new study medicine NNC0174-1213, a study medicine called "cagrilintide" or a placebo (a "dummy medic...

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Male
Target Recruitment
177
Inclusion Criteria
  • Male.
  • Age 18-55 years (both inclusive) at the time of signing the informed consent.
  • Body mass index (BMI) between 27.0 and 34.9 kilogram per meter square (kg/m^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
  • Body weight more than or equal to (>=) 80.0 kilograms (kg) at screening.
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Read More
Exclusion Criteria
  • Known or suspected hypersensitivity to study intervention(s) or related products.
  • Exposure to an investigational medicinal product within 2 months or 5 half-lives of the investigational medicinal product (if known), whichever is longer, before screening.
  • Participants report prior receipt of an amylin and/or calcitonin receptor agonist within the last 6 months.
  • Impaired liver function defined as any of the below:
  • Aspartate aminotransferase (AST) more than or equal to (>=) 2 times upper limit of normal at screening
  • Alanine aminotransferase (ALT) more than or equal to (>=) 2 times upper limit of normal at screening
  • Bilirubin more than (>) 1.5 times upper limit of normal at screening (except if known or proven Gilbert's syndrome)
  • Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than (<) 75 milliliters per minute per 1.73 square meter (mL/min/1.73 m^2) at screening.
  • Glycated haemoglobin (HbA1c) more than or equal to (>=) 6.5 percent (%) (48 millimoles per mole (mmol/mol) at screening.
  • Any clinically significant body weight change more than or equal to (>=) 5 percent (%) self-reported change) or dieting attempts (e.g., participation in a weight reduction program) within 90 days before screening .
  • Any disorder, unwillingness or inability which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol.
  • Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values:
  • Vitamin D (25-hydroxycholecalciferol) less than (<) 12 nanogram per milliliter (ng/mL) (30 nanometer (nM) at screening
  • Parathyroid hormone (PTH) outside normal range at screening
  • Total calcium outside normal range at screening
  • Calcitonin more than or equal to (>=) 50 nanogram per liter (ng/L) at screening
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Part A: NNC0174-1213 (SD1-SD5)NNC0174-1213 APart A: Single ascending dose (SAD) of NNC0174-1213 will be administered in cohorts 1-5.
Part A: NNC0174-1213 (SD1-SD5)Cagrilintide BPart A: Single ascending dose (SAD) of NNC0174-1213 will be administered in cohorts 1-5.
Part A: NNC0174-1213 (SD1-SD5)Placebo A (NNC0174 1213 A)Part A: Single ascending dose (SAD) of NNC0174-1213 will be administered in cohorts 1-5.
Part A: Cagrilintide (SDA and SDB)NNC0174-1213 APart A: Single ascending dose (SAD): Cagrilintide SDA will be administered in cohort 1 and 2. Cagrilintide SDB will be administered in cohort 3 and 4.
Part A: Cagrilintide (SDA and SDB)Cagrilintide BPart A: Single ascending dose (SAD): Cagrilintide SDA will be administered in cohort 1 and 2. Cagrilintide SDB will be administered in cohort 3 and 4.
Part A: Cagrilintide (SDA and SDB)Placebo A (NNC0174 1213 A)Part A: Single ascending dose (SAD): Cagrilintide SDA will be administered in cohort 1 and 2. Cagrilintide SDB will be administered in cohort 3 and 4.
Part A: PlaceboNNC0174-1213 APart A: Single ascending dose (SAD) of placebo will be administered to cohorts 1-5.
Part A: PlaceboCagrilintide BPart A: Single ascending dose (SAD) of placebo will be administered to cohorts 1-5.
Part A: PlaceboPlacebo A (NNC0174 1213 A)Part A: Single ascending dose (SAD) of placebo will be administered to cohorts 1-5.
Part B: NNC0174-1213 (MD1-MD5)NNC0174-1213 APart B: Multiple ascending doses (MAD) of NNC0174-1213 will be administered to cohorts 1-5.
Part B: NNC0174-1213 (MD1-MD5)Cagrilintide BPart B: Multiple ascending doses (MAD) of NNC0174-1213 will be administered to cohorts 1-5.
Part B: NNC0174-1213 (MD1-MD5)Placebo A (NNC0174 1213 A)Part B: Multiple ascending doses (MAD) of NNC0174-1213 will be administered to cohorts 1-5.
Part B: Cagrilintide (MDA)NNC0174-1213 APart B: Multiple ascending doses (SAD) of Cagrilintide MDA will be administered to cohorts 1-5.
Part B: Cagrilintide (MDA)Cagrilintide BPart B: Multiple ascending doses (SAD) of Cagrilintide MDA will be administered to cohorts 1-5.
Part B: Cagrilintide (MDA)Placebo A (NNC0174 1213 A)Part B: Multiple ascending doses (SAD) of Cagrilintide MDA will be administered to cohorts 1-5.
Part B: PlaceboNNC0174-1213 APart B: Multiple ascending doses (MAD) of placebo will be administered to cohorts 1-5.
Part B: PlaceboCagrilintide BPart B: Multiple ascending doses (MAD) of placebo will be administered to cohorts 1-5.
Part B: PlaceboPlacebo A (NNC0174 1213 A)Part B: Multiple ascending doses (MAD) of placebo will be administered to cohorts 1-5.
Primary Outcome Measures
NameTimeMethod
Part A: Number of treatment emergent adverse events (TEAE) reported by participants exposed to NNC0174 1213From NNC0174 1213 administration (Day 1) to completion of the end of study visit (Day 46)

Number of events

Part B: Number of treatment emergent adverse events (TEAE)From first administration (Day 1) to completion of the end of study visit (Day 67)

Number of events

Secondary Outcome Measures
NameTimeMethod
Part A: AUC; area under the NNC0174 1213 plasma concentration-time curveFrom pre-dose on Day 1 to completion of the end of study visit (Day 46)

measured in hour\*nanomoles per liter (h\*nmol/L).

Part A: Cmax; maximum observed NNC0174 1213 plasma concentrationFrom pre-dose on Day 1 to completion of the end of study visit (Day 46)

measured in nanomoles per liter (nmol/L).

Part B: AUC; area under the NNC0174 1213 plasma concentration-time curveFrom first administration (Day 1) to completion of the end of study visit (Day 67)

measured in h\*nmol/L.

Part B: Cmax; maximum observed NNC0174 1213 plasma concentrationFrom first administration (Day 1) to completion of the end of study visit (Day 67)

measured in nmol/L.

Trial Locations

Locations (1)

ICON Early Phase Services, LLC

🇺🇸

Salt Lake City, Utah, United States

© Copyright 2024. All Rights Reserved by MedPath